应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
ALNY 阿尔尼拉姆制药公司
未开盘 02-26 16:00:00 EST
331.24
+3.88
+1.19%
盘后
332.00
+0.76
+0.23%
18:43 EST
最高
333.47
最低
322.00
成交量
88.03万
今开
328.67
昨收
327.36
日振幅
3.50%
总市值
437.61亿
流通市值
417.88亿
总股本
1.32亿
成交额
2.89亿
换手率
0.70%
流通股本
1.26亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增100.90%，机构观点偏正面
财报Agent · 02-05
财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增100.90%，机构观点偏正面
阿尔尼拉姆制药公司第四季度Amvuttra与Onpattro净产品收入分别约为8.27亿美元及3200万美元
美股速递 · 01-12
阿尔尼拉姆制药公司第四季度Amvuttra与Onpattro净产品收入分别约为8.27亿美元及3200万美元
阿里拉姆制药涨0.58% 股价突破400美元大关
市场透视 · 01-07
阿里拉姆制药涨0.58% 股价突破400美元大关
Peptidream与阿尔尼拉姆制药公司宣布在siRNA结合物发现合作中取得关键里程碑
投资观察 · 2025-12-18
Peptidream与阿尔尼拉姆制药公司宣布在siRNA结合物发现合作中取得关键里程碑
阿里拉姆制药涨2.28% 股价突破400美元大关
市场透视 · 2025-12-17
阿里拉姆制药涨2.28% 股价突破400美元大关
阿尔尼拉姆制药公司将投资2.5亿美元增强美国制造设施的酶连接平台以满足全球对RNAi治疗的日益增长的需求
美股速递 · 2025-12-17
阿尔尼拉姆制药公司将投资2.5亿美元增强美国制造设施的酶连接平台以满足全球对RNAi治疗的日益增长的需求
纳斯达克宣布渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数
投资观察 · 2025-12-13
纳斯达克宣布渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数
纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数
美股速递 · 2025-12-13
纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数
纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司
老虎资讯综合 · 2025-12-13
纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司
阿尔尼拉姆制药公司宣布董事会成员变更
投资观察 · 2025-12-03
阿尔尼拉姆制药公司宣布董事会成员变更
异动解读 | 阿尔尼拉姆制药公司股价盘中大跌8.38%，疑因季度业绩不及预期
异动解读 · 2025-10-30
异动解读 | 阿尔尼拉姆制药公司股价盘中大跌8.38%，疑因季度业绩不及预期
阿尔尼拉姆制药公司第三季度净产品收入为12.49亿美元，超出Ibes预估的9.46亿美元
美股速递 · 2025-10-30
阿尔尼拉姆制药公司第三季度净产品收入为12.49亿美元，超出Ibes预估的9.46亿美元
阿尔尼拉姆制药公司公布2025年第三季度财务业绩并强调近期进展
美股速递 · 2025-10-30
阿尔尼拉姆制药公司公布2025年第三季度财务业绩并强调近期进展
Alnylam宣布Zilebesiran的Zenith全球3期心血管结果试验首位患者开始给药
美股速递 · 2025-10-01
Alnylam宣布Zilebesiran的Zenith全球3期心血管结果试验首位患者开始给药
Helios-B三期研究新数据显示：Vutrisiran治疗ATTR-CM患者胃肠道不良事件发生率更低
美股速递 · 2025-09-28
Helios-B三期研究新数据显示：Vutrisiran治疗ATTR-CM患者胃肠道不良事件发生率更低
BridgeBio(BBIO.US)指控辉瑞(PFE.US)、Alnylam(ALNY.US)在数十亿美元心脏病药市场采用“争议策略”竞争
智通财经 · 2025-09-12
BridgeBio(BBIO.US)指控辉瑞(PFE.US)、Alnylam(ALNY.US)在数十亿美元心脏病药市场采用“争议策略”竞争
里程碑式Helios-B三期研究新数据在2025年欧洲心脏病学会大会上发布，证实维特西然对ATTR-CM患者的长期心血管获益
美股速递 · 2025-08-31
里程碑式Helios-B三期研究新数据在2025年欧洲心脏病学会大会上发布，证实维特西然对ATTR-CM患者的长期心血管获益
阿里拉姆制药盘中异动 股价大涨5.07%报249.13美元
市场透视 · 2025-03-01
阿里拉姆制药盘中异动 股价大涨5.07%报249.13美元
HC Wainwright & Co.：维持Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价由400.00美元调整至500.00美元。
金融界 · 2025-02-25
HC Wainwright & Co.：维持Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价由400.00美元调整至500.00美元。
加拿大投资银行集团：维持Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价由384.00美元调整至385.00美元。
金融界 · 2025-02-18
加拿大投资银行集团：维持Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价由384.00美元调整至385.00美元。
公司概况
公司名称：
阿尔尼拉姆制药公司
所属市场：
NASDAQ
上市日期：
--
主营业务：
Alnylam Pharmaceuticals, Inc.是一家特拉华州公司，成立于2003年5月。该公司是一家研发基于RNA或RNAi干涉为新型治疗手段的生物制药公司。RNAi是一种在生物体内细胞中自然产生的选择性沉默及调控表达的特定基因。由于许多疾病是因为特定基因的不适当活动引起的，通过RNAi对于基因的选择性沉默能力可以为治疗许多人类疾病提供一种新的途径。公司认为，通过RNAi原理工作的药物有潜力成为的一种新的药物分类，诸如小分子药物、蛋白质药物以及抗体药物等。通过已经建立RNAi的知识产权以及专业技术，公司正在开发一套生物化学方法以帮助公司建立一个系统，通过该系统可以研发改进RNAi对于各种疾病的治疗方案。
发行价格：
--
{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"阿尔尼拉姆制药公司","latestPrice":331.24,"timestamp":1772139600000,"preClose":327.36,"halted":0,"volume":880311,"hourTrading":{"tag":"盘后","latestPrice":332,"preClose":331.24,"latestTime":"18:43 EST","volume":102157,"amount":33840009.38,"timestamp":1772149384080,"change":0.76,"changeRate":0.002294,"amplitude":0.053655},"delay":0,"changeRate":0.011852394916911032,"floatShares":126154848,"shares":132113818,"eps":2.33,"marketStatus":"未开盘","change":3.88,"latestTime":"02-26 16:00:00 EST","open":328.67,"high":333.47,"low":322,"amount":289422444.38745,"amplitude":0.035038,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.33,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772182800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":327.36,"preHourTrading":{"tag":"盘前","latestPrice":326.98,"preClose":327.36,"latestTime":"09:28 EST","volume":130,"amount":42449.8685,"timestamp":1772116087853,"change":-0.38,"changeRate":-0.001161,"amplitude":0.014021},"postHourTrading":{"tag":"盘后","latestPrice":332,"preClose":331.24,"latestTime":"18:43 EST","volume":102157,"amount":33840009.38,"timestamp":1772149384080,"change":0.76,"changeRate":0.002294,"amplitude":0.053655},"volumeRatio":0.905004,"impliedVol":0.4091,"impliedVolPercentile":0.2829},"requestUrl":"/m/hq/s/ALNY/wiki","defaultTab":"wiki","newsList":[{"id":"1128963715","title":"财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增100.90%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1128963715","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128963715?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:16","pubTimestamp":1770257799,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司将于2026年02月12日发布最新季度财报，市场关注收入与盈利改善的延续性，并聚焦核心产品组合的放量表现及费用效率变化。市场一致预期显示，本季度阿尔尼拉姆制药公司收入预计为11.73亿美元，同比增长100.90%；调整后每股收益预计为1.16美元，同比增长185.85%；息税前利润预计为2.04亿美元，同比增长321.65%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增100.90%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"1194639707","title":"阿尔尼拉姆制药公司第四季度Amvuttra与Onpattro净产品收入分别约为8.27亿美元及3200万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194639707","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194639707?lang=zh_cn&edition=full","pubTime":"2026-01-12 06:11","pubTimestamp":1768169473,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司最新财务数据显示，其核心药物Amvuttra在第四季度展现出强劲的市场表现，净产品收入达到约8.27亿美元。与此同时，另一款重要产品Onpattro同期净产品收入约为3200万美元。这两款疗法的销售表现共同反映了公司在特定治疗领域的市场渗透力和商业执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4139","BK4548","LU0114720955.EUR","ALNY","LU0320765992.SGD","BK4588","LU0889565916.HKD","BK4585","LU0109394709.USD"],"gpt_icon":0},{"id":"2601944808","title":"阿里拉姆制药涨0.58% 股价突破400美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2601944808","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601944808?lang=zh_cn&edition=full","pubTime":"2026-01-07 02:12","pubTimestamp":1767723140,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日02时12分，阿里拉姆制药股票出现波动，股价急速拉升0.58%。截至发稿，该股报400.12美元/股，成交量64.8612万股，换手率0.49%，振幅3.92%。最近的财报数据显示，该股实现营业收入12.49亿美元，净利润2.51亿美元，每股收益1.91美元，毛利10.49亿美元，市盈率1332.08倍。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为0.76%。阿里拉姆制药公司简介：艾拉伦制药是RNA干扰治疗研究的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107021220a6fb4b7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107021220a6fb4b7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4504","LU1152091754.HKD","LU2226246903.HKD","BK4587","LU0067412154.USD","LU1051768304.USD","LU0106959298.USD","LU0320765992.SGD","IE00BF5LJ272.USD","LU0047713382.USD","BK4503","BK4579","LU0553294199.USD","LU0979878070.USD","LU0114720955.EUR","LU1048596156.SGD","LU0880133367.SGD","BK4531","IE00B0JY6N72.USD","BK4502","BK4139","LU0348816934.USD","LU1152091168.USD","BK4548","LU1242518931.SGD","LU1046421795.USD","LU1769817179.HKD","LU0651946864.USD","BK4122","LU0072462343.USD","LU0052756011.USD","LU0310800965.SGD","BK4538","LU1880383366.USD","LU0072913022.USD","LU0661504455.SGD","LU0251143458.SGD","BK4554","BK4535","LU1823568750.SGD","LU0889565916.HKD","LU0348814723.USD","BK4505","LU1046422090.SGD","LU0797268264.HKD","BK4581","ALNY","LU1003077747.HKD","LU1008478684.HKD","BK4588","LU0949170772.SGD","LU0882574055.USD","BK4585","LU1105468828.SGD","LU1688375341.USD","LU0651947912.USD","LU0109394709.USD","LU0328353924.USD","LU0918141887.USD","BK4533","LU1242518857.USD","BK4575","LU0128525689.USD","LU0738911758.USD","BK4527","BK4558","LU1051769294.HKD","BK4220","LU0918141705.HKD","IE00BFMHRM44.USD","BK4534","BK4614","LU0821914370.USD","ALBmain","BK4543","BK4565","LU1048588211.SGD","LU1282648689.USD","LU1267930227.SGD","LU1515016050.SGD","LU0501845795.SGD","LU0545039389.USD","LU1235294995.USD","BK4526","LU1769817096.USD","BK4607","BK4524","LU2148611432.USD"],"gpt_icon":1},{"id":"1141535458","title":"Peptidream与阿尔尼拉姆制药公司宣布在siRNA结合物发现合作中取得关键里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1141535458","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141535458?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:23","pubTimestamp":1766060587,"startTime":"0","endTime":"0","summary":"12月18日（路透社）- PeptiDream Inc <4587.T>::* Peptidream与阿尔尼拉姆制药公司宣布在siRNA结合物发现合作中取得关键里程碑，证明了肽配体介导的靶向siRNA输送到特定的肝外组织。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","ALNY","LU0882574055.USD","LU0889565916.HKD","BK4588","LU0114720955.EUR","BK4585","BK4139","BK4548","LU0109394709.USD"],"gpt_icon":0},{"id":"2592285948","title":"阿里拉姆制药涨2.28% 股价突破400美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2592285948","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592285948?lang=zh_cn&edition=full","pubTime":"2025-12-17 23:06","pubTimestamp":1765984007,"startTime":"0","endTime":"0","summary":"北京时间2025年12月17日23时06分，阿里拉姆制药股票出现波动，股价大幅上涨2.28%。截至发稿，该股报400.09美元/股，成交量10.1661万股，换手率0.08%，振幅1.83%。最近的财报数据显示，该股实现营业收入12.49亿美元，净利润2.51亿美元，每股收益1.91美元，毛利10.49亿美元，市盈率1332.23倍。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为0.36%。阿里拉姆制药公司简介：艾拉伦制药是RNA干扰治疗研究的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217230647a6ae8c29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217230647a6ae8c29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BF5LJ272.USD","LU0889565916.HKD","LU1769817179.HKD","LU1051768304.USD","LU1823568750.SGD","LU0109394709.USD","LU1003077747.HKD","LU1515016050.SGD","LU0979878070.USD","LU0738911758.USD","BK4558","LU1152091754.HKD","LU0882574055.USD","LU0348816934.USD","BK4505","LU1048588211.SGD","ALBmain","BK4531","BK4526","LU1046421795.USD","LU0821914370.USD","BK4575","LU1242518857.USD","LU0545039389.USD","BK4581","LU0128525689.USD","LU0501845795.SGD","LU2148611432.USD","LU1880383366.USD","LU1769817096.USD","BK4122","IE00B0JY6N72.USD","BK4614","IE00BFMHRM44.USD","LU1688375341.USD","LU0106959298.USD","LU0114720955.EUR","BK4588","LU0047713382.USD","BK4503","LU1105468828.SGD","LU0328353924.USD","LU1235294995.USD","LU1282648689.USD","LU0072462343.USD","LU0797268264.HKD","LU1046422090.SGD","LU2226246903.HKD","LU0067412154.USD","BK4534","BK4502","BK4527","LU1242518931.SGD","LU0651947912.USD","LU0880133367.SGD","LU0072913022.USD","LU0553294199.USD","BK4607","LU0320765992.SGD","LU1048596156.SGD","BK4535","BK4524","BK4554","LU0310800965.SGD","BK4220","LU1152091168.USD","LU1008478684.HKD","BK4504","BK4139","BK4587","LU0052756011.USD","BK4538","LU0348814723.USD","LU0918141887.USD","LU0949170772.SGD","LU1267930227.SGD","LU0651946864.USD","BK4548","BK4585","LU0918141705.HKD","BK4543","LU0251143458.SGD","LU0661504455.SGD","LU1051769294.HKD","BK4579","BK4533","BK4565","ALNY"],"gpt_icon":1},{"id":"1119407729","title":"阿尔尼拉姆制药公司将投资2.5亿美元增强美国制造设施的酶连接平台以满足全球对RNAi治疗的日益增长的需求","url":"https://stock-news.laohu8.com/highlight/detail?id=1119407729","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119407729?lang=zh_cn&edition=full","pubTime":"2025-12-17 21:04","pubTimestamp":1765976640,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司将投资2.5亿美元，增加酶连接平台到美国制造设施，以应对全球对RNAi治疗日益增长的需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","ALNY","LU0889565916.HKD","LU0109394709.USD","BK4588","BK4139","LU0114720955.EUR","BK4585","BK4548","LU0320765992.SGD"],"gpt_icon":0},{"id":"1166333259","title":"纳斯达克宣布渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1166333259","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166333259?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:21","pubTimestamp":1765588891,"startTime":"0","endTime":"0","summary":"12月12日（路透社）- 纳斯达克公司宣布：*纳斯达克公司 - 宣布纳斯达克100指数的重组，将于12月22日生效* 纳斯达克公司：六家公司将被添加到纳斯达克100指数* 纳斯达克公司：渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数* 纳斯达克公司：阿尔尼拉姆制药公司、FERROVIAL、INSMED、Monolithic Power Systems、希捷科技、西部数据将被添加到纳斯达克100指数。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670627923.USD","IE00BN0W2W23.USD","LU0889565916.HKD","LU2360107325.USD","LU0320765992.SGD","LU1035773651.USD","LU1861214812.USD","LU1496350502.SGD","LU0444973449.USD","BK4504","LU1992135399.USD","BK4140","LU2272731782.SGD","CDW","IE00BN0W2V16.EUR","LU2473716301.USD","BK4613","LU0353189680.USD","MPWR","LU0109391861.USD","LU2360106780.USD","LU0724618433.USD","LU1046421795.USD","STX","BK4170","IE00BFMHRM44.USD","LU0124384867.USD","LU0320765059.SGD","LU1823568750.SGD","LU1815336760.USD","LU1854103824.USD","LU1069347547.HKD","TTD","LU0274383776.USD","BK4605","LU0672654240.SGD","LU1267930730.SGD","LU1670628061.USD","LU0203345920.USD","LU0234570918.USD","LU2250418816.HKD","LU0109394709.USD","LU0957808578.USD","LU1992135472.HKD","LU1861215975.USD","BK4528","ON","LU2272731865.HKD","BIIB","LU0114720955.EUR","LU1235294995.USD","LU0348723411.USD","LU2931357623.SGD","BK4512","LU0203347892.USD","BK4533","LU0444971666.USD","LU0882574055.USD","LU1720051108.HKD","LU0006061336.USD","IE00BN0W2T93.GBP","IE00B19Z9P08.USD","WDC","LU1720051017.SGD","LU1854104046.USD","LU2322448957.HKD","LU0823411888.USD","BK4585","LU1978683503.SGD","LU1548497426.USD","BK4588","LU0353189763.USD","LU0708995401.HKD","LU1861220033.SGD","LU2089985449.USD","LU2272731600.USD","IE00BZ199S13.USD","IE00B19Z9Z06.USD","LU2087625088.SGD","LULU","BK4009","BK4141","IE00B894F039.SGD","ALNY","LU1852331112.SGD","LU0476273544.USD","LU2357305700.SGD","BK4202","BK4139","LU2360107168.USD","LU2322448791.USD","LU0081259029.USD","LU1642822529.SGD","IE00BD6J9T35.USD","BK4548","LU2298322129.HKD","GFS","LU2290526834.HKD","BK4023","LU0056508442.USD","LU1861219969.SGD","BK4532"],"gpt_icon":0},{"id":"1131212462","title":"纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1131212462","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131212462?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:09","pubTimestamp":1765588155,"startTime":"0","endTime":"0","summary":"纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0edbc198404a72334f079a67157af149","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1046421795.USD","LU1670627923.USD","BK4139","IE00B3QW5Z07.USD","LU1992135472.HKD","LU0053671581.USD","LU1992135399.USD","LU2250418816.HKD","LU0476273544.USD","LU1235294995.USD","LU1642822529.SGD","LU2360107168.USD","LU2473716301.USD","BK4548","LU0203347892.USD","LU0114720955.EUR","IE00BN0W2W23.USD","IE00B894F039.SGD","LU2210149790.SGD","LU2322448791.USD","LU0882574055.USD","LU1267930730.SGD","LU1852331112.SGD","SG9999014021.USD","LU1069347547.HKD","LU2089985449.USD","WDC","LU0203345920.USD","BK4112","INSM","LU2272731782.SGD","LU0056508442.USD","LU1861215975.USD","LU0109394709.USD","IE00BN0W2T93.GBP","LU2087625088.SGD","LU0274383776.USD","BK4512","LU0957808578.USD","LU2272731600.USD","LU2360106780.USD","LU0353189680.USD","IE00BN0W2V16.EUR","LU0353189763.USD","LU1861220033.SGD","LU2322448957.HKD","LU0314104364.USD","LU0444971666.USD","BK4588","LU2272731865.HKD","LU0444973449.USD","NDAQ","BK4585","LU0081259029.USD","LU0320765992.SGD","SG9999014013.SGD","BK4141","LU0320765059.SGD","MPWR","SG9999014039.USD","LU0006061336.USD","IE00B19Z9Z06.USD","BK4170","LU2095319765.USD","IE00BGHQF748.EUR","LU1815336760.USD","LU1670628061.USD","IE00BD6J9T35.USD","IE00B19Z9P08.USD","STX","LU0889565916.HKD","IE00B64PRP62.GBP","LU0708995401.HKD","LU2931357623.SGD","LU2210150020.SGD","LU1823568750.SGD","LU1035773651.USD","LU0672654240.SGD","IE00BKPKM429.USD","LU0109391861.USD","ALNY","LU2290526834.HKD","SG9999014005.SGD"],"gpt_icon":0},{"id":"1117266784","title":"纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1117266784","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117266784?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:08","pubTimestamp":1765588106,"startTime":"0","endTime":"0","summary":"12月13日，纳斯达克公司宣布纳斯达克100指数成份股调整将于12月22日生效。6家公司即将被纳入纳斯达克100指数。分别是艾尼拉姆制药公司、费罗维亚集团、英斯梅德公司、单片电源系统公司、希捷科技控股有限公司和西部数据公司。而有6家被移出，百健公司（Biogen）CDW公司、格芯公司、露露乐蒙、安森美半导体和交易台公司（The Trade Desk）。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","BIIB","GFS","CDW","MPWR","FER","LULU","NDAQ","ON","TTD","STX","WDC"],"gpt_icon":0},{"id":"1137897631","title":"阿尔尼拉姆制药公司宣布董事会成员变更","url":"https://stock-news.laohu8.com/highlight/detail?id=1137897631","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137897631?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:17","pubTimestamp":1764767856,"startTime":"0","endTime":"0","summary":"12月3日 - 阿尔尼拉姆制药公司宣布董事会成员的变更。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","LU0882574055.USD","BK4585","BK4588","LU0109394709.USD","LU0320765992.SGD","ALNY","BK4139","LU0114720955.EUR","LU0889565916.HKD"],"gpt_icon":0},{"id":"1182765016","title":"异动解读 | 阿尔尼拉姆制药公司股价盘中大跌8.38%，疑因季度业绩不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1182765016","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182765016?lang=zh_cn&edition=full","pubTime":"2025-10-30 22:15","pubTimestamp":1761833754,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司（股票代码：ALNY）今日盘中股价大幅下挫，截至交易时段中期，跌幅已达8.38%，引发市场广泛关注。\n\n消息面上，阿尔尼拉姆制药公司于今日早间发布了2025年第三季度财务业绩报告。这份季度报告似乎未能满足投资者的期望，导致股价出现明显回调。\n\n虽然具体财务数据尚未公开，但市场分析人士推测，公司可能出现收入增长放缓、盈利不及预期或下调全年业绩指引等情况。生物制药行业竞争激烈，新药研发进展、销售表现以及监管环境等因素都可能影响公司的财务状况。投资者对这些关键指标的失望情绪可能是导致股价大跌的主要原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALNY"],"gpt_icon":0},{"id":"1144954749","title":"阿尔尼拉姆制药公司第三季度净产品收入为12.49亿美元，超出Ibes预估的9.46亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144954749","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144954749?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:02","pubTimestamp":1761825738,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司第三季度净产品收入为12.49亿美元，超过了Ibes预估的9.46亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","ALNY","LU0320765992.SGD","BK4588","LU0889565916.HKD","BK4585","LU0109394709.USD"],"gpt_icon":0},{"id":"1116585058","title":"阿尔尼拉姆制药公司公布2025年第三季度财务业绩并强调近期进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1116585058","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116585058?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:01","pubTimestamp":1761825709,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司公布2025年第三季度财务业绩并强调近期进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","BK4585","LU0109394709.USD","LU0889565916.HKD","BK4588","BK4548","ALNY"],"gpt_icon":0},{"id":"1100025121","title":"Alnylam宣布Zilebesiran的Zenith全球3期心血管结果试验首位患者开始给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1100025121","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100025121?lang=zh_cn&edition=full","pubTime":"2025-10-01 19:30","pubTimestamp":1759318225,"startTime":"0","endTime":"0","summary":"Alnylam宣布Zilebesiran的Zenith全球3期心血管结果试验首位患者开始给药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","LU0320765992.SGD","LU0109394709.USD","BK4585","ALNY","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"1152381200","title":"Helios-B三期研究新数据显示：Vutrisiran治疗ATTR-CM患者胃肠道不良事件发生率更低","url":"https://stock-news.laohu8.com/highlight/detail?id=1152381200","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152381200?lang=zh_cn&edition=full","pubTime":"2025-09-28 23:16","pubTimestamp":1759072584,"startTime":"0","endTime":"0","summary":"来自Helios-B三期临床研究的最新数据表明，接受Vutrisiran治疗的ATTR-CM（转甲状腺素蛋白心肌淀粉样变性）患者出现胃肠道不良事件的比例显著降低。\n这项研究结果为Vutrisiran在治疗ATTR-CM方面的安全性提供了重要证据，特别是在减少患者胃肠道相关副作用方面展现出明显优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","LU0320765992.SGD","LU0109394709.USD","BK4139","BK4588","BK4585","LU0889565916.HKD","ALNY"],"gpt_icon":0},{"id":"2566943391","title":"BridgeBio(BBIO.US)指控辉瑞(PFE.US)、Alnylam(ALNY.US)在数十亿美元心脏病药市场采用“争议策略”竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2566943391","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566943391?lang=zh_cn&edition=full","pubTime":"2025-09-12 08:27","pubTimestamp":1757636836,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，BridgeBio Pharma正凭借一款心脏病药物与辉瑞、Alnylam Pharmaceuticals展开竞争。该公司称其药物疗效更优且成本更低，但同时指控竞争对手在这个价值数十亿美元的市场中采用“有争议的策略”进行竞争。BridgeBio表示，其研发的药物Attruby拥有充分的科学数据支持，足以成为该疾病的“标准治疗方案”，但市场竞争的激烈程度远超预期。库马尔则称，BridgeBio已就辉瑞的推广行为向OPDP提交信函，但尚未看到该机构采取行动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1344379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","LU0321505439.SGD","LU0289739699.SGD","LU0320765992.SGD","BK4139","BK4599","SG9999011175.SGD","SGXZ57979304.SGD","BK4534","ALNY","LU0234572021.USD","LU1057294990.SGD","LU0306807586.USD","SG9999003800.SGD","SG9999001176.USD","BK4568","PFE","BK4505","IE00B19Z3B42.SGD","LU1894683264.USD","SG9999001176.SGD","BK4548","LU0985481810.HKD","SG9999013999.USD","BBIO","IE0002270589.USD","BK4007","LU1066053197.SGD","LU1066051498.USD","LU0456855351.SGD","SG9999002224.SGD","LU0868494617.USD","IE00BBT3K403.USD","BK4592","LU1883839398.USD","LU0321505868.SGD","LU0109394709.USD","LU1894683348.USD","LU1023059063.AUD","LU0170899867.USD","BK4585","LU0058720904.USD","IE00BLSP4452.SGD","LU0225771236.USD","LU0306806265.USD","SG9999002232.USD","IE00BLSP4239.USD","LU0889565916.HKD","BK4588","LU0225284248.USD"],"gpt_icon":0},{"id":"1171394945","title":"里程碑式Helios-B三期研究新数据在2025年欧洲心脏病学会大会上发布，证实维特西然对ATTR-CM患者的长期心血管获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1171394945","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171394945?lang=zh_cn&edition=full","pubTime":"2025-08-31 17:15","pubTimestamp":1756631725,"startTime":"0","endTime":"0","summary":"里程碑式Helios-B三期研究的最新数据在2025年欧洲心脏病学会大会上正式发布，研究结果证实了维特西然在治疗转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)方面具有显著的长期心血管获益效果。\n这项重要研究为维特西然在ATTR-CM治疗领域的临床应用提供了更加坚实的科学依据，展现了该药物在改善患者长期心血管健康方面的积极作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4585","BK4588","LU0109394709.USD","BK4139","LU0320765992.SGD","ALNY","LU0889565916.HKD"],"gpt_icon":0},{"id":"2516301361","title":"阿里拉姆制药盘中异动 股价大涨5.07%报249.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516301361","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516301361?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:55","pubTimestamp":1740776141,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时55分，阿里拉姆制药股票出现波动，股价急速拉升5.07%。截至发稿，该股报249.13美元/股，成交量65.6826万股，换手率0.51%，振幅5.14%。机构评级方面，在所有34家参与评级的机构中，71%的券商给予买入建议，24%的券商给予持有建议，5%的券商给予卖出建议。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为0.72%。阿里拉姆制药公司简介：艾拉伦制药是RNA干扰治疗研究的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010455429896c845&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010455429896c845&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0797268264.HKD","BK4524","LU0072913022.USD","BK4504","BK4585","LU1515016050.SGD","LU0821914370.USD","LU1046421795.USD","BK4558","LU0348816934.USD","LU1282648689.USD","BK4538","LU1152091168.USD","ALNY","BK4588","LU0067412154.USD","BK4548","LU1008478684.HKD","BK4527","LU0128525689.USD","LU0501845795.SGD","LU0651946864.USD","BK4579","BK4220","BK4543","LU1105468828.SGD","LU1688375341.USD","BK4139","IE00BFMHRM44.USD","LU0918141705.HKD","LU0251143458.SGD","LU1051768304.USD","BK4503","LU0348814723.USD","LU0918141887.USD","LU1046422090.SGD","BK4581","BK4505","BK4587","BK4526","LU0310800965.SGD","BK4534","BK4607","LU1823568750.SGD","LU1048596156.SGD","BK4535","BK4533","LU2226246903.HKD"],"gpt_icon":1},{"id":"2514776864","title":"HC Wainwright & Co.：维持Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价由400.00美元调整至500.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514776864","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514776864?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:25","pubTimestamp":1740414342,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价由400.00美元调整至500.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25002548356460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ALNY"],"gpt_icon":0},{"id":"2512815626","title":"加拿大投资银行集团：维持Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价由384.00美元调整至385.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512815626","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512815626?lang=zh_cn&edition=full","pubTime":"2025-02-18 19:55","pubTimestamp":1739879745,"startTime":"0","endTime":"0","summary":"加拿大投资银行集团：维持Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价由384.00美元调整至385.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/18195548236352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ALNY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0941},{"period":"3month","weight":-0.2646},{"period":"6month","weight":-0.2668},{"period":"1year","weight":0.3351},{"period":"ytd","weight":-0.1768}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alnylam Pharmaceuticals, Inc.是一家特拉华州公司，成立于2003年5月。该公司是一家研发基于RNA或RNAi干涉为新型治疗手段的生物制药公司。RNAi是一种在生物体内细胞中自然产生的选择性沉默及调控表达的特定基因。由于许多疾病是因为特定基因的不适当活动引起的，通过RNAi对于基因的选择性沉默能力可以为治疗许多人类疾病提供一种新的途径。公司认为，通过RNAi原理工作的药物有潜力成为的一种新的药物分类，诸如小分子药物、蛋白质药物以及抗体药物等。通过已经建立RNAi的知识产权以及专业技术，公司正在开发一套生物化学方法以帮助公司建立一个系统，通过该系统可以研发改进RNAi对于各种疾病的治疗方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.028609},{"month":2,"riseRate":0.454545,"avgChangeRate":0.002007},{"month":3,"riseRate":0.47619,"avgChangeRate":-0.013154},{"month":4,"riseRate":0.380952,"avgChangeRate":-0.019703},{"month":5,"riseRate":0.619048,"avgChangeRate":0.04124},{"month":6,"riseRate":0.636364,"avgChangeRate":0.064494},{"month":7,"riseRate":0.681818,"avgChangeRate":0.106925},{"month":8,"riseRate":0.590909,"avgChangeRate":0.037005},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"阿尔尼拉姆制药公司","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿尔尼拉姆制药公司,ALNY,阿尔尼拉姆制药公司股票,阿尔尼拉姆制药公司股票老虎,阿尔尼拉姆制药公司股票老虎国际,阿尔尼拉姆制药公司行情,阿尔尼拉姆制药公司股票行情,阿尔尼拉姆制药公司股价,阿尔尼拉姆制药公司股市,阿尔尼拉姆制药公司股票价格,阿尔尼拉姆制药公司股票交易,阿尔尼拉姆制药公司股票购买,阿尔尼拉姆制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}